6505--36C77026Q0061/RFI/Domestic Sources Rx_MedSurge Amendment 0001

Amendment / Modification

This amendment modifies Solicitation 36C77026Q0061. The key changes are:

• Response Date/Time Extension: The deadline for receipt of offers has been extended to September 30, 2026, at 09:00 AM Central Time (CDTX).
• RFI Status Clarification: The Request for Information (RFI) remains unrestricted, and all interested vendors are encouraged to submit information.
• Closing Date Correction: The RFI closing date is extended to October 1, 2026, at 09:00 AM CST.

This amendment primarily affects the "Response Date/Time/Zone" and "Description" sections of the original solicitation.

The extension of the response date and RFI closing date provides additional time for vendors to prepare and submit their offers or information. All other terms and conditions of the original solicitation remain unchanged.

Request for Information (RFI)

This RFI is issued by the Department of Veterans Affairs (VA), Network Contracting Office 15 (NCO 15) for market research and procurement planning purposes. The VA's Consolidated Mail Outpatient Pharmacy (CMOP) is seeking to identify domestic small and large businesses capable of manufacturing pharmaceutical end items for its Open Market (OM) purchases. This RFI does not constitute a solicitation for quotes or proposals and does not commit the government to any acquisition approach or contract award.

The VA is interested in domestic manufacturers of pharmaceuticals and ancillary items that support CMOP's OM needs. Specific NAICS codes of interest are 325412 (Pharmaceutical Preparation Manufacturing) and 325413 (In-Vitro Diagnostic Substance Manufacturing). A list of specific pharmaceutical items and their uses is provided, but it is not exhaustive. Manufacturers are also encouraged to identify other domestically produced pharmaceuticals they can supply.

Interested manufacturers should submit a capability statement by March 15, 2026, 4:30 pm CT. Responses should include company information (name, address, POC, manufacturing facility location, socioeconomic status, business size, SAM UEI), product information (list of products, NDC numbers, treatment usage, authorized distributors, average cost), operational capability (production capacity, stockout history, replenishment timelines, commercial sales), and contracting information (GSA/FSS/NAC contracts, suggested NAICS/PSC codes). Responses must be emailed to Michael McAlhaney (michael.mcalhaney@va.gov) and Tresanna Tacia (tresanna.tacia@va.gov) with a specific subject line format.

The VA is particularly interested in identifying domestic small businesses, with the highest interest in Service-Disabled Veteran Owned Small Businesses (SDVOSB) and Veteran Owned Small Businesses (VOSB) manufacturers.

Manufacturers must demonstrate compliance with federal, state, and local regulations and the capacity to support all seven CMOP sites. Prospective contractors must be registered in the System for Award Management (SAM) database. All information received will be handled as proprietary if marked. Respondents are responsible for all associated costs.

Form / Attachment / Pricing Sheet

This document is an Excel spreadsheet containing detailed information and data fields related to pharmaceutical products. It appears to be a request for information (RFI) or a data collection tool to gather manufacturer and pharmaceutical specifics for potential acquisition planning.

• Pharmaceutical Specifics: Includes fields for Generic Name, Active Ingredients, FDA Approved NDC(s), FDA Approval #, existing Government-wide/Agency-wide Contract status, Treatment Usage, Manufacturing Facility location, and Authorized Distributors.

• Manufacturer Specifics: Includes fields for Manufacturer Name, Physical Address, Manufacturing Capacity, Frequency of Stockouts, SAM UEI #, Commercial Sales history, Average Cost to commercial entities, and Socio-Economic Status.

• Item List (Sheet3): A list of specific pharmaceutical items with their station item number, description, and intended treatment.

• The request is for acquisition planning of commercially available items via open market channels at fair and reasonable pricing.

• Pharmaceutical NDCs without FDA approval should not be submitted.

• NDCs should reflect the manufacturer, not a repackager. If an NDC correlates to multiple manufacturing facilities, including non-domestic ones, this must be noted, along with how domestically produced items are differentiated.

This document provides potential bidders with a clear list of pharmaceutical items and the specific data points the government is seeking to understand manufacturing capabilities, regulatory compliance, and pricing for potential future procurements. Bidders should review the "Items" sheet to identify relevant products and the data fields in the other sheets to understand the information required for a response.